title: Infliximab for the treatment of posterior uveitis with retinal neovascularization in Behçet disease.
abstract: OBJECTIVE
  To report a case of posterior uveitis with retinal neovascularization in a patient with Behçet disease treated with infliximab.
  
  
  METHODS
  A 50-year-old man with a history of recurrent relapses of ocular inflammation despite immunosuppressive therapy developed retinal neovascularization near the optic disk. The patient was treated with infliximab and followed up for 12 months.
  
  
  RESULTS
  Retinal neovascularization regressed 8 months after the first anti-tumor necrosis factor (TNF) treatment and with six infusions of infliximab. The ocular inflammation resolved almost completely.
  
  
  CONCLUSIONS
  The result suggests that anti-TNF therapy may be effective in the treatment of retinal neovascularization caused by panuveitis in Behçet disease.
authors.affiliation: Eye Clinic, Department of Oto-Neuro-Ophthalmological Surgical Sciences, University of Firenze, Firenze--Italy. fabriziogiansanti@interfree.it
authors.forename: F
authors.initials: F
authors.lastname: Giansanti
authors.forename: M L
authors.initials: ML
authors.lastname: Barbera
authors.forename: G
authors.initials: G
authors.lastname: Virgili
authors.forename: B
authors.initials: B
authors.lastname: Pieri
authors.forename: L
authors.initials: L
authors.lastname: Emmi
authors.forename: U
authors.initials: U
authors.lastname: Menchini
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001528:Behcet Syndrome / Q000150:complications / Q000188:drug therapy*; D005451:Fluorescein Angiography; D005654:Fundus Oculi; D006801:Humans; D000069285:Infliximab; D008297:Male; D015861:Retinal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome; D015866:Uveitis, Posterior / Q000188:drug therapy* / Q000209:etiology; D014792:Visual Acuity
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab